Skip to main content
2026 Prospectus
The Healthcare ExecutiveExecutive News

Lilly sets 5-day 340B data deadline. How hospitals should respond

Eli Lilly has told an initial group of 340B hospitals to start submitting claims-level data within five business days or lose discounted pricing on its drugs, escalating a dispute that hospital groups call unlawful.

Lilly sets 5-day 340B data deadline. How hospitals should respond

Executive takeaway

Lilly’s deadline turns a policy dispute into an immediate margin question. Know your dollar exposure by product and site before deciding whether to submit data or contest the demand.

Article

What Lilly is demanding

In a June 1 letter to the Health Resources and Services Administration, Lilly said it has begun notifying covered entities that have not submitted claims data. Wholesalers will be told to stop offering 340B pricing to those hospitals until they comply, and the company plans to widen enforcement in the coming weeks. In February, Lilly expanded its data requirement to include dispensing through hospitals’ in-house pharmacies.

Lilly says the data helps it detect duplicate discounts, support audits and meet its Inflation Reduction Act obligations. It reports that about 70% of covered entities buying its drugs, roughly 2,350 organizations, have already submitted in-house claims data, and that two-thirds of critical access hospitals are compliant. The company also claims some large hospitals have coordinated a boycott.

The hospital response

The American Hospital Association said on June 2 that the policy is unlawful and will add cost and administrative burden for hospitals serving vulnerable patients. It noted that Lilly had not answered a May 13 AHA proposal for a neutral, government-run data clearinghouse. 340B Health, which represents more than 1,600 hospitals, urged HRSA to warn the company about enforcement.

The fight comes as hospitals press on other fronts to protect 340B savings. Mount Sinai Health System, Michigan Medicine and the University of Kansas Health System have filed separate suits alleging that CVS Caremark kept about $250 million in 340B savings through spread pricing from 2020 to 2025.

Decisions for leadership

Each affected hospital faces a hard choice: comply with a policy it may view as unlawful, or accept the loss of discounts on a major manufacturer’s products while regulators and courts sort out the dispute. Neither option is free.

  • Quantify the exposure: annual 340B savings on Lilly products by site, covering both contract pharmacy and in-house dispensing.
  • Assess what data submission would require from pharmacy, IT and compliance teams, and how patient information would be protected.
  • Coordinate with counsel and your state hospital association before responding, and keep records of any wholesaler notices.
  • Brief the board. A loss of discounts would likely hit margins at safety-net and rural sites first.

Archive entry for Jun 2, 2026, added Nov. 11, 2026.

Sources

Quarterly Brief

Get the Quarterly Brief by email.

A practical executive agenda for hospital and health system leaders, four times a year.

Sent by The Healthcare Executive. Unsubscribe at any time. See our Privacy Policy.